Agenda for November 2026 Cancer Treatments (CTAC) meeting
Information on what the Cancer Treatments Advisory Committee (CTAC) will be considering at its upcoming meeting in November 2026.
Matters Arising
Supplier correspondence for ribociclib for people with early-stage breast cancer
The Committee will discuss correspondence regarding the trial results for ribociclib (CDK 4/6 inhibitors) for adjuvant HR positive/HER-2 negative early breast cancer, which was previously discussed at the November 2025 CTAC meeting [PDF, 535 KB].
Application for ribociclib(external link)
Applications
Cemiplimab (branded as Libtayo) for skin cancer
The Committee will discuss an application for cemiplimab for the treatment of people living with squamous cell carcinoma. This application is for first line treatment, for people whose cancer is advanced or has spread and cannot be removed with surgery or radiation therapy.
Application for cemiplimab(external link)
Pembrolizumab (branded as KEYTRUDA) for head and neck cancer
The Committee will discuss an application for pembrolizumab for the treatment of people living with resectable, locally advanced squamous cell head and neck cancer.
Application for pembrolizumab(external link)
Mogamulizumab (branded as Poteligeo) for Sézary Syndrome
The Committee will discuss an application for mogamulizumab for the treatment of people living with Sézary syndrome that has returned or has not responded to previous treatment.
Application for mogamulizumab(external link)
Advisory meeting agenda setting
The scheduling and agenda setting process for advisory meetings considers multiple factors. We aim to balance the relative priorities of clinical advice needed across indications, the factors for consideration for each application (for example unmet health need), the time since applications were received and the internal and advisor resource available to support each meeting.